Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 1

Status

Completed 2Withdrawn 1Terminated 1Not yet recruiting 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Gynecologic 5Sarcoma 1

Conditions

Ovarian Neoplasms 805Uterine Cervical Neoplasms 412Fallopian Tube Neoplasms 289Endometrial Neoplasms 287Carcinoma, Ovarian Epithelial 252Neoplasms 95Recurrence 83Breast Neoplasms 83Peritoneal Neoplasms 66Uterine Neoplasms 55Colorectal Neoplasms 55Uterine Cervical Dysplasia 50Sarcoma 49Vulvar Neoplasms 47Carcinoma, Non-Small-Cell Lung 45Neoplasm Metastasis 44Stomach Neoplasms 42Pancreatic Neoplasms 36Melanoma 34Testicular Neoplasms 32Lung Neoplasms 32Prostatic Neoplasms 29Vaginal Neoplasms 28Papillomavirus Infections 25Carcinoma 25Head and Neck Neoplasms 23Esophageal Neoplasms 23Carcinoma, Renal Cell 23Small Cell Lung Carcinoma 22Urinary Bladder Neoplasms 21

Interventions

pembrolizumab 2lenvatinib 1anlotinib 1Paclitaxel 1NVP-BKM120 1Injections 1Gemcitabine 1Doxorubicin 1Docetaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Advanced Endometrial Cancer × Gynecologic × Clear all
NCT05481645 2026-01-09

Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Terminated
71 enrolled
GynecologicSarcoma

Advanced Endometrial Cancer

NCT05106127 2025-12-08

Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem

Evergreen Therapeutics, Inc.

Phase 2 Not yet recruiting
28 enrolled
Gynecologic

Advanced Endometrial Cancer

NCT04574284 2025-05-28

A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Completed
170 enrolled
Gynecologic

Advanced Endometrial Cancer

NCT06046274 2024-04-30

GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer

Genmab

Phase 2 Withdrawn
Gynecologic

Advanced Endometrial Cancer

NCT01289041 2019-05-30

BKM120 as Second-line Therapy for Advanced Endometrial Cancer

Novartis

Phase 2 Completed
70 enrolled 8 charts
Gynecologic

Advanced Endometrial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡